Dena Howard

Dena Howard

Profile

I joined the Clinical Trials Reserach Unit in 2004 and progressed to Principal Statistician level in 2010, providing statistical leadership for the Chronic Lymphocytic Leukaemia (CLL) portfolio of trials within the Cancer Research Division.

In 2018 I completed a part-time Doctoral Research Fellowship, funded by the National Institute for Health Research (NIHR), to investigate the statistical implications of adding an emerging therapy into an ongoing randomised controlled trial. The focus of the research was on multiple testing adjustment requirements for multiple hypotheses with shared control data, the necessity for adaptive analysis methods, and provision of general guidance and recommendations for researchers wishing to adapt a trial in this way. The findings were applied to the FLAIR trial in chronic lymphocytic leukaemia, in which a new experimental therapy was added during the recruitment period.

 

 

 

 

Responsibilities

  • Late Phase Cancer Division
  • Scientific Lead for the Chronic Lymphocytic Leukaemia (CLL) portfolio

Research interests

I primarily work across late phase trials in oncology. My key responsibility is for development, statistical oversight and research methodology of the CLL programme, from concept and design through to analysis and reporting of phase II and III clinical trials. I am a core member of NCRI UK CLL Subgroup. I am Scientific Lead for our portfolio of CLL trials including FLAIR, GALACTIC, COSMIC, ARCTIC and ADMIRE.

Through my PhD research I have specialised in efficient flexible and adaptive designs and multiple testing requirements. I am using this knowledge to inform trial designs going forward in order to design trials that are as efficient as possible, often using Master Protocols to answer multiple questions within the same trial structure.

Qualifications

  • PhD, University of Leeds, 2018
  • MSc Statistics, Distinction, University of Sheffield, 2001
  • BSc Hons, 1st Class, University of Leeds, 2000

Research groups and institutes

  • Leeds Institute of Clinical Trials Research